12:00 AM
 | 
Jan 13, 2014
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Neumedicines preclinical data

In non-human primates, a single low-dose subcutaneous injection of HemaMax significantly improved the survival rate at 60 days after exposure to lethal radiation vs. placebo (56% vs. 36%, p<0.05). In a comparator arm, 18 consecutive days of treatment with Neupogen filgrastim, a human G-CSF, did not improve the 60-day survival rate vs. placebo (31% vs. 36%). Additionally, a single dose of HemaMax plus 18 consecutive days of Neupogen non-significantly improved...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >